

Applicant : Lars Hellman
Serial No. : 09/401,636
Filed : September 22, 1999
Page : 2

Attorney's Docket No.: 10223-006001

6. (Amended) The immunogenic polypeptide of claim 5, wherein said first region comprises said CH2 domain of IgE. ~~F~~

7. (Amended) The immunogenic polypeptide of claim 5, wherein said second region comprises said CH4 domain of IgE. ~~F~~

25. (Amended) An immunogenic polypeptide, comprising a self IgE domain and a non-self IgE domain, wherein said immunogenic polypeptide is effective to induce an anti-self IgE response in a mammal, wherein said self IgE domain is a CH3 domain of IgE, and wherein said immunogenic polypeptide lacks a CH1 domain of IgE.

27. (Amended) The immunogenic polypeptide of claim 26, wherein said non-self IgE domain comprises an IgE domain present in a non-placental mammal.

30. (Amended) The immunogenic polypeptide of claim 25, wherein said non-self IgE domain is a CH2 domain of IgE.

31. (Amended) The immunogenic polypeptide of claim 25, wherein said non-self IgE domain is a CH4 domain of IgE.

32. (Amended) The immunogenic polypeptide of claim 25, wherein said non-self IgE domain is a CH2 domain of IgE, wherein said polypeptide further comprises a CH4 domain of IgE, said self IgE domain being located between said CH2 domain of IgE and said CH4 domain of IgE.

33. (Amended) An immunogenic polypeptide, comprising a self IgE portion and a non-self IgE domain, wherein said immunogenic polypeptide is effective to induce an anti-self IgE response in a mammal, wherein said self IgE portion comprises an N-terminal portion of a CH3 domain of IgE, and wherein said N-terminal portion is amino acid number 117 through 178 of Figure 2a.

Applicant : Lars Hellman
Serial No. : 09/401,636
Filed : September 22, 1999
Page : 3

Attorney's Docket No.: 10223-006001

35. (Amended) The immunogenic polypeptide of claim 34, wherein said non-self IgE domain comprises an IgE domain present in a non-placental mammal.
38. (Amended) The immunogenic polypeptide of claim 33, wherein said non-self IgE domain is a CH2 domain of IgE.
39. (Amended) The immunogenic polypeptide of claim 33, wherein said non-self IgE domain is a CH4 domain of IgE.
40. (Amended) The immunogenic polypeptide of claim 33, wherein said non-self IgE domain is a CH2 domain of IgE, wherein said polypeptide further comprises a CH4 domain of IgE, said self IgE portion being located between said CH2 domain of IgE and said CH4 domain of IgE.
41. (Amended) An immunogenic polypeptide, comprising a self IgE domain and a non-self IgE domain, wherein said immunogenic polypeptide is effective to induce an anti-self IgE response in a mammal, and wherein said non-self IgE domain is an IgE domain present in a non-placental mammal.
45. (Amended) The immunogenic polypeptide of claim 41, wherein said non-self IgE domain is a CH2 domain of IgE.
46. (Amended) The immunogenic polypeptide of claim 41, wherein said non-self IgE domain is a CH4 domain of IgE.
47. (Amended) The immunogenic polypeptide of claim 41, wherein said non-self IgE domain is a CH2 domain of IgE, wherein said polypeptide further comprises a CH4 domain of IgE, said self IgE domain being located between said CH2 domain of IgE and said CH4 domain of IgE.

Applicant : Lars Hellman
Serial No. : 09/401,636
Filed : September 22, 1999
Page : 4

Attorney's Docket No.: 10223-006001

48. (Amended) A polypeptide, comprising a self IgE domain and a non-self IgE domain, wherein said polypeptide lacks light chain Ig sequences and is effective to induce an anti-self IgE response in a mammal, wherein said self IgE domain is a CH3 domain of IgE.

50. (Amended) The polypeptide of claim 49, wherein said non-self IgE domain comprises an IgE domain present in a non-placental mammal.

52. (Amended) The polypeptide of claim 48, wherein said non-self IgE domain is a CH2 domain of IgE.

53. (Amended) The polypeptide of claim 48, wherein said non-self IgE domain is a CH4 domain of IgE.

54. (Amended) The polypeptide of claim 48, wherein said non-self IgE domain is a CH2 domain of IgE, wherein said polypeptide further comprises a CH4 domain of IgE, said self IgE domain being located between said CH2 domain of IgE and said CH4 domain of IgE.--